STORM Therapeutics is a University of Cambridge spin-out, translating the groundbreaking work of Professors Tony Kouzarides and Eric Miska in RNA epigenetics into the discovery of first-in-class drugs in oncology and other diseases.
STORM is backed by blue chip investors Cambridge Innovation Capital, Merck Ventures, Pfizer Ventures and Touchstone Innovations, who share the founders’ ambitions to build a world-leading company in the field. The company raised £12 million series A funding in June 2016 and occupies modern, well-equipped laboratories on the Babraham Research Campus near Cambridge, UK.
www.stormtherapeutics.com
